New work from David R. Liu’s lab uses AI to give enzyme design a leg up. AI-redesigned starting points and outcomes enhance protein evolution 🧬 Thanks to the authors for choosing Twist DNA to support this research! Read the paper👇

AI-redesigned starting points and outcomes enhance protein evolution - Nature

A workflow using artificial intelligence-redesigned starting points to evolve enzymes with improved properties compared with those evolved from natural proteins is established.

nature.com

What if you could supercharge CAR-T therapy & use it as a treatment beyond cancer? Combining CAR-T with CRISPR @ TALEN is enabling more precise, scalable cell therapies beyond cancer for autoimmune, fibrotic, & genetic disorders: www.insideprecisionmedicine.com/topics/preci... @twistbioscience.com

Gene-Edited CAR T Expands Rare Disease Horizons

Combining CAR T with CRISPR or TALEN is enabling more precise, scalable cell therapies for autoimmune, fibrotic, and genetic disorders.

insideprecisionmedicine.com

Twist's integrated NGS solutions enable scalable, cost-effective research. Emily Leproust: “Researchers get deeper, more reliable data with fewer sequencing reads per sample compared to both arrays and competing NGS panels.” 👉 www.asianscientist.com/2026/07/spon... @twistbioscience.com

Fresh science just dropped. 🧬 From product news to new publications & research highlights, this month's newsletter is full of updates you won't want to miss NGS fans, biotech experts, antibody specialists, virologists, researchers & scientists, read on:

Top News from Twist Bioscience, July 2026

Explore the latest genomics innovations from Twist Bioscience, including complex gene synthesis, exome sequencing, MRD, NGS, and AI-driven antibody research

linkedin.com

Science is better with good DNA...and good socks.🧦🧬 We had a great time stopping by Caltech to deliver some Twist swag & catch up with longtime customers and Twist users. There's nothing better than seeing how Twist DNA enables research Thanks for the warm welcome, @caltech.edu

WES, WGS, what? Considering whole exome sequencing (WES) or whole genome sequencing (WGS)? This great article featuring input from our CEO and co-founder (and chemist!) Emily Leproust has some fantastic tips for making the right choice:

Whole Exome or Whole Genome Sequencing: Tips for Making the Right Choice

One method is not necessarily superior to the other.

biocompare.com

🎉 Announcing Complex Genes, now made simple with Twist! ✅ Watch our announcement video ✅ Get to know Complex Genes ✅ See how to keep your projects moving when they involve challenging DNA. @twistbioscience.com

CRISPR gets a power boost from AI-designed ‘molecular scissors’ New work from the Doudna lab! Key takeaways: • Evolution-aware AI designed enzyme variants more likely to retain function. • Engineered RNA-guided nucleases showed improved genome-editing activity… @innovativegenomics.bsky.social

We’re bringing back a Twist classic! Whether you wear them solo or pair them with sandals (we won’t tell anyone 🤫), a fresh pair of Twist socks is the ultimate lab accessory. Learn how to claim your pair here: www.twistbioscience.com/promo/summer... *Terms and conditions apply @twistbioscience.com

What if a negative test isn't the end of the story? When PCR couldn't identify the virus behind a deadly hemorrhagic fever outbreak, Twist's Comprehensive Viral Panel and whole genome sequencing helped identify the rare Bundibugyo Ebola strain: biopharmaboardroom.com/expert-opini...

A new study from the @broadinstitute.org demonstrates a low-cost exome sequencing approach called BGE (Blended Genome Exome) that offers high-quality exome sequencing that can scale to hundreds of thousands of samples while enabling rare variant discovery:

Low-cost genome sequencing approach is powering genetics research on mental illness and many other studies

The Blended Genome Exome approach delivers high-quality, unbiased genetic data at a quarter of the cost of the leading sequencing method.

broadinstitute.org

👀 MRD & cancer researchers: This substack from James Hadfield focuses on “exploring the enabling technologies that could fundamentally democratize MRD testing, moving it out of large centralised labs & into community oncology centres near patients.”

Did you see Josh Kerr destroy the men’s mile world record? 3 minutes and 42.66 seconds… He’s fast, and you know what else is fast? Twist Express Genes! 🏃‍♂️ Clonal Genes made in the US to your specifications and shipped to you in as few as 4 days.* www.twistbioscience.com/products/gen...

Anyone following the World Cup? 🏆 If so, respond with an emoji of which team you're rooting for! ⚽ Since Twist is a data-driven company, we conducted an informal poll. Twisters from around the world weighed in about who they are cheering on, and the results are in…

“Twist Exome 2.0 capture consistently delivered superior results for DNA extracted from non-peripheral blood tissues […] provides robust performance & is particularly well-suited for samples where DNA quality may be compromised…”

We are happy to see this paper out in Frontiers this week! The team including members from Microsoft, IBBIS, IGSC, Battelle, and more test biosecurity screening down to oligo-lengths with AI-engineered sequences. @erichorvitz.bsky.social @twistbioscience.com @jdiggans.bsky.social

Frontiers | The limits of sequence-based biosecurity screening tools in the age of AI-assisted protein design

Rapid advancements in AI have enabled significant progress in protein and nucleic acid design, but they also pose biosecurity challenges. We examine the vuln...

frontiersin.org

That’s a wrap on the Twist Oncology Roadshow in Singapore & India! Experts in the field gathered to discuss everything from MRD & solid tumors to comprehensive genomic profiling & liquid biopsy. Special thanks to all the panelists, organizers, & attendees! @twistbioscience.com

Fast + efficient + novel antibody development? New from the Institute for Protein Innovation & @harvardmed.bsky.social, led by principal scientist Deepash Kothiwal, reports a novel framework for making synthetic recombinant antibodies that can generate data specifically optimized for ML integration.

Our CEO and co-founder Emily Leproust, and Christine Wormuth, former U.S. secretary of the army, president and CEO of @nti.org discuss supporting scientific innovation while reducing deliberate misuse of AI. Read why it is important here: www.newsweek.com/us-china-mus...

Superior uniformity, deeper insights. The Twist Bioscience NGS advantage Watch our talk led by Maria Harbo at the recent congress of ESHG held in beautiful Gothenburg 🇸🇪 here: m.youtube.com/watch?v=VpF3... @twistbioscience.com

Shout out to the IPI team, our collaborators (including @deboramarks.bsky.social & @alainchedotal.bsky.social), and @twistbioscience.com for devising a clever combinatorial gene synthesis method to create billions of differing CDR3s!

🤖 AI: Here's 10K new DNA designs 🧑‍🔬 Researchers: Great, who can actually make them? At Twist, we're making even the toughest DNA sequences routine so science doesn't have to wait for the impossible. Emily Leproust explains how: www.the-scientist.com/the-power-of...

🧬 Decode the Virome with Unmatched Precision Stop searching for the "needle in the haystack" & start seeing the whole field Tracking an emerging outbreak or profiling complex viral communities? Our Broad Viral NGS Panel provides the resolution to move from detection to discovery

Traditional surveillance can miss the silent spread of viruses, but new approaches are changing the game. Jelle Matthijnssens shares groundbreaking research comparing emergency department indoor air and citywide wastewater monitoring for respiratory and enteric viruses…

Vibe check, we’re about half way through the year, which one a we feeling describes the first part of 2026?

Top news from Twist!  This month was super busy so we distilled it into our June newsletter. Topics include: Ebola & hantavirus outbreaks, mandatory synthetic DNA screening in the age of AI, Patrick Finn on modern drug discovery:

Base Pair Bulletin | Twist Bioscience

Top news from Twist! This month was super busy so we distilled it into our June newsletter: •Hear Twist President and COO Patrick Finn discuss synthetic DNA and modern drug discovery •Learn about h...

linkedin.com

New customer work you won’t want to miss… JAM-2, opens up one of the biggest frontiers in drug discovery by designing highly selective antibodies that can target proteins once thought unreachable inside cells. Read the report here👇

Summer brings time for learning at your leisure, browse our free webinar library! ☀️ Learn about topics including: AI, base editors, antibody discovery, liquid biopsy, cancer research, infectious disease, drug development, synthetic DNA, & MUCH more: www.twistbioscience.com/resources/we...

“John Dye: The 2026 Ebola Outbreak Got a Four-Month Head Start Because No One Ran the Right Test” Hear John Dye of USAMRIID discuss the state of the Bundibugyo Ebola virus outbreak including testing, treatments, and more with Vincent Racaniello on a special edition of the TWiV

We are missing #ESHG2026 already! The recording of our corporate session with Maria Harbo, Claes Ladenvall, & Isabell Schumann will be available soon. Thanks to everyone who visited with us and sharing your work. We loved hearing about it and also sharing our latest. @twistbioscience.com